<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Characteristics of medications used in the treatment of pulmonary hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Characteristics of medications used in the treatment of pulmonary hypertension</h1>
<div class="graphic"><div class="figure"><div class="ttl">Characteristics of medications used in the treatment of pulmonary hypertension</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Route of administration</td> <td class="subtitle1">Dose range (adult)</td> <td class="subtitle1">Half-life</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Prostacyclin pathway agonists</td> </tr> <tr> <td class="indent1">Epoprostenol</td> <td>Continuous IV infusion via central venous catheter</td> <td> <p>1 to 12 nanograms/kg/minute initially</p> Dose titrated up every 1 to 2 weeks until therapeutic response or dose limiting toxicity occurs</td> <td> <p>3 to 5 minutes (single dose)</p> 15 minutes (continuous infusion)</td> </tr> <tr> <td class="indent1" rowspan="2">Treprostinil</td> <td>Continuous IV infusion via central venous catheter or continuous subcutaneous infusion</td> <td> <p>0.625 to 1.25 nanograms/kg/minute initially</p> Dose titrated up every 1 to 2 weeks until therapeutic response or dose limiting toxicity occurs</td> <td>4 hours</td> </tr> <tr> <td>Inhaled</td> <td> <p>1 to 3 inhalations (ie, 6 to 18 micrograms), 4 times daily initially</p> Maintenance dose may be gradually titrated up to 9 inhalations (ie, 54 micrograms), 4 times daily</td> <td>4 hours</td> </tr> <tr> <td class="indent1">Iloprost</td> <td>Inhaled</td> <td>2.5 to 5 micrograms, 6 to 9 times daily</td> <td>20 to 30 minutes (half-life of pulmonary vasodilating effect)</td> </tr> <tr> <td class="indent1">Selexipag</td> <td> <p>Oral</p> Intravenous formulation is available for temporary use when unable to take oral therapy</td> <td> <p>200 to 1600 micrograms twice daily</p> <p>Dose titrated up every 1 to 2 weeks until therapeutic response or dose limiting toxicity occurs</p> For intravenous formulation, see labeling for dosing</td> <td> <p>0.8 to 2.5 hours (selexipag)</p> 6.2 to 13.5 hours (active metabolite)</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Endothelin receptor antagonists</td> </tr> <tr> <td class="indent1">Bosentan</td> <td>Oral</td> <td> <p>62.5 to 125 mg, 2 times daily</p> Dose is adjusted for low body weight or drug interactions<sup>*</sup></td> <td>5 hours</td> </tr> <tr> <td class="indent1">Ambrisentan</td> <td>Oral</td> <td>5 to 10 mg daily</td> <td>9 hours</td> </tr> <tr> <td class="indent1">Macitentan</td> <td>Oral</td> <td>10 mg per day</td> <td>14 to 18 hours (parent drug)</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Nitric oxide-cyclic guanosine monophosphate enhancers</td> </tr> <tr> <td class="indent1" colspan="4"><strong>Soluble guanylate cyclase stimulant</strong></td> </tr> <tr> <td class="indent2">Riociguat</td> <td>Oral</td> <td>Initial dose 0.5 to 1 mg 3 times daily, titrated up by 0.5 mg 3 times per day every 2 weeks until therapeutic response or dose limiting toxicity occurs (maximum dose 2.5 mg 3 times daily)</td> <td>12 hours</td> </tr> <tr> <td class="indent1" colspan="4"><strong>Phosphodiesterase type 5 inhibitors</strong></td> </tr> <tr> <td class="indent2" rowspan="2">Sildenafil</td> <td>Oral</td> <td>20 mg, 3 times daily</td> <td>4 hours</td> </tr> <tr> <td>IV</td> <td> <p>10 mg, 3 times daily</p> Dose is adjusted for drug interactions<sup>*</sup></td> <td>4 hours</td> </tr> <tr> <td class="indent2">Tadalafil</td> <td>Oral</td> <td> <p>40 mg daily</p> Dose is adjusted for drug interactions<sup>*</sup></td> <td>35 hours</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Calcium channel blockers<sup>¶</sup></td> </tr> <tr> <td class="indent1">Nifedipine</td> <td>Oral</td> <td>Start 30 mg per day. Increase to the maximum tolerated dose over days to weeks.</td> <td>7 hours</td> </tr> <tr> <td class="indent1">Diltiazem extended-release</td> <td>Oral</td> <td>Start 120 mg per day. Increase to the maximum tolerated dose over days to weeks.</td> <td>6 to 9 hours</td> </tr> <tr> <td class="indent1">Amlodipine</td> <td>Oral</td> <td>Start 2.5 mg per day. Increase to the maximum tolerated dose over days to weeks.</td> <td>30 to 50 hours</td> </tr> </tbody></table></div><div class="graphic_lgnd">Drugs used to treat PH should only be administered by PH experts. For patients on medications for other conditions, specific drug interactions and management suggestions may be determined by using Lexi-Interact, the drug interactions program included with UpToDate.</div><div class="graphic_footnotes"><p>PH: pulmonary hypertension.</p>
<p>* Refer to individual Lexicomp drug monographs included with UpToDate.</p>
¶ Choice of calcium channel blocker is based upon the patient's heart rate. Refer to text.</div><div class="graphic_reference">Data from:
<ol>
<li>Montani D, Gunther S, Dorfmuller P, et al. Pulmonary arterial hypertension. ORJD 2013; 8:97.</li>
<li>Coghlan G, Geaine S, Gatzoulis M, et al. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008; 63:ii1.</li>
</ol></div><div id="graphicVersion">Graphic 50798 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
